Clinical Trial Update: Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of atezolizumab in relapsed or refractory Hodgkin lymphoma was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Hodgkin Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2019-11-14